DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Phase 1

Completed

Conditions: Hematologic Malignancy

First Posted Date: 2007-05-21

Last Posted Date: 2012-03-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00476177

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

ALL Adult Consortium Trial: Adult ALL Trial

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Doxorubicin
Drug: Cytarabine
Drug: Methotrexate
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Methylprednisone
Drug: Hydrocortisone Sodium Succinate
Drug: Dexamethasone
Drug: 6-MP
Drug: PEG-Asparaginase
Drug: Imatinib
Drug: Etoposide
Procedure: Radiation Therapy
Drug: E. coli Asparaginase

First Posted Date: 2007-05-21

Last Posted Date: 2025-03-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 112

Registration Number: NCT00476190

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Boston, Boston, Massachusetts, United States

and more 12 locations

Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Docetaxel
Drug: ZD6474

First Posted Date: 2007-04-11

Last Posted Date: 2013-07-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00459043

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood, Illinois, United States

Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery

Not Applicable

Terminated

Conditions: Prostate Cancer

Interventions: Dietary Supplement: omega-3 fatty acids
Procedure: biopsy

First Posted Date: 2007-04-11

Last Posted Date: 2018-07-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 232

Registration Number: NCT00458549

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Phase 1

Completed

Conditions: Metastatic, Androgen Independent Prostate Cancer
Prostate Cancer

Interventions: Drug: RAD001
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2007-04-11

Last Posted Date: 2016-05-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00459186

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 2 locations

Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Biological: GM-K562 vaccine
Procedure: stem cell transplantation

First Posted Date: 2007-03-01

Last Posted Date: 2020-09-17

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT00442130

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

First Posted Date: 2007-02-16

Last Posted Date: 2012-10-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00436072

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase 1

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy

First Posted Date: 2007-02-05

Last Posted Date: 2017-04-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 28

Registration Number: NCT00431210

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Natural History Study of Patients With Chronic Myelogenous Leukemia

Completed

Conditions: Leukemia

First Posted Date: 2007-02-01

Last Posted Date: 2017-01-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 48

Registration Number: NCT00429910

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Procedure: Leukemia cell harvest

First Posted Date: 2007-01-29

Last Posted Date: 2020-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 65

Registration Number: NCT00428233

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy